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Abstract 
Background: Elevated levels of serum C‑reactive protein (CRP) have been reported to have prognostic significance 
in lung cancer patients. This study aimed to further identify CRP‑bound components as prognostic markers for lung 
cancer and validate their prognostic value.
Methods: CRP‑bound components obtained from the serum samples from lung cancer patients or healthy controls 
were analyzed by differential proteomics analysis. CRP‑bound serum amyloid A (CRP‑SAA) was evaluated by co‑
immunoprecipitation (IP). Serum samples from two independent cohorts with lung cancer (retrospective cohort, 242 
patients; prospective cohort, 222 patients) and healthy controls (159 subjects) were used to evaluate the prognostic 
value of CRP‑SAA by enzyme‑linked immunosorbent assay.
Results: CRP‑SAA was identified specifically in serum samples from lung cancer patients by proteomic analysis. 
CRP binding to SAA was confirmed by co‑IP in serum samples from lung cancer patients and cell culture media. The 
level of CRP‑SAA was significantly higher in patients than in healthy controls (0.37 ± 0.58 vs. 0.03 ± 0.04, P < 0.001). 
Elevated CRP‑SAA levels were significantly associated with severe clinical features of lung cancer. The elevation of CRP‑
SAA was associated with lower survival rates for both the retrospective (hazard ration [HR] = 2.181, 95% confidence 
interval [CI] = 1.641–2.897, P < 0.001) and the prospective cohorts (HR = 2.744, 95% CI = 1.810–4.161, P < 0.001). 
Multivariate Cox analysis showed that CRP‑SAA was an independent prognostic marker for lung cancer. Remarkably, 
in stages I–II patients, only CRP‑SAA, not total SAA or CRP, showed significant association with overall survival in two 
cohorts. Moreover, univariate and multivariate Cox analyses also showed that only CRP‑SAA could be used as an inde‑
pendent prognostic marker for early‑stage lung cancer patients.
Conclusion: CRP‑SAA could be a better prognostic marker for lung cancer than total SAA or CRP, especially in early‑
stage patients.
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Background
Lung cancer is the most common cause of cancer-asso-
ciated death worldwide [1]. In China, the incidence and 
mortality of lung cancer are the highest among all can-
cers [2–4]. Early diagnosis and appropriate treatment are 
key factors for the improvement of prognosis. Predictive 
and prognostic biomarkers are needed to divide early-
stage lung cancer patients into subgroups [5] and can 
improve medical decision-making in delivering the most 
suitable treatment.
Recently, chronic inflammation has been found to be 
associated with tumor progression, and many inflam-
matory factors could serve as prognostic biomark-
ers for some tumors [6, 7]. Lung cancer presents as a 
chronic inflammatory disease [8, 9]. Several studies have 
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suggested that the elevation of serum C-reactive protein 
(CRP) could be used as a prognostic factor for lung can-
cer [10–12].
CRP, a classical member of the pentraxin family, has 
high affinity for many types of autologous and extrinsic 
ligands. Autologous ligands include damaged cell mem-
branes, apoptotic cells, plasma lipoproteins, phospho-
lipids, ribonucleoprotein particles, extracellular matrix 
proteins, and Fc-γ receptors. Extrinsic ligands include 
various constituents of many microorganisms. Once 
aggregated or bound to macromolecular ligands, CRP 
activates the complement system to form membrane 
attack complex, which in turn attacks target molecules 
or cells. Therefore, CRP plays a key scavenger role in 
the clearance of abnormal cells or apoptotic cells [13, 
14]. CRP is secreted by hepatocytes in response to the 
inflammatory cytokines produced by the tumor micro-
environment [15], and CRP can enter the tumor micro-
environment through the circulation, where it binds to 
a variety of autologous and extrinsic ligands and plays a 
key role in the clearance of tumor cells [16].
As CRP has the ability to bind to various ligands, a sub-
set of the circulating CRP pool may exist in the form of 
CRP complexes. Because elevated circulating levels of 
CRP have been frequently found in lung cancer patients 
[10–12], we hypothesized that CRP may bind to ligands 
expressed by lung cancer cells or tumor-associated cells 
and that CRP-bound components in the serum of lung 
cancer patients may be different from those of healthy 
subjects. Therefore, CRP-bound complexes in the serum 
may be potential prognostic biomarkers of lung cancer.
In an effort to identify possible novel biomarkers to fur-
ther refine the prognostic prediction accuracy of serum 
CRP levels for lung cancer, we used differential proteom-
ics technology to identify a specific type of CRP complex 
in serum samples from lung cancer patients. We also 
evaluated the value of this CRP complex as a potential 




Serum samples were collected from two independent 
cohorts of lung cancer patients recruited from the Sun 
Yat-sen University Cancer Center (SYSUCC). Patients 
recruited for the retrospective cohort (n  =  242) were 
first diagnosed and treated between 2002 and 2004, and 
follow-up data from these patients were available up 
to 2010. Patients recruited for the prospective cohort 
(n = 222) were first diagnosed and treated between 2008 
and 2010, and they were followed up to 2014. Detailed 
patient characteristics are described in Table  1. Serum 
samples were also obtained from 159 healthy controls 
recruited from SYSUCC staff volunteers between 2008 
and 2010.
The selection criteria for lung cancer patients were as 
follows: histologically confirmed lung cancer, complete 
documentation of medical history, primary lung cancer 
features and disease course, completeness of follow-up 
examinations, and absence of systemic treatment for at 
least 6 weeks before blood withdrawal. Clinical stage was 
assessed according to the seventh edition of the Lung Can-
cer Staging International Division, which was published by 
the Union for International Cancer Control (UICC) and 
the International Association for the Study of Lung Cancer 
(IASLC) in 2009. To use these serum samples for research 
purposes, prior informed consent from the patients and 
approval from the Institute Research Ethics Committee of 
SYSUCC were obtained. The selection criteria for healthy 
controls were as follows: good physical status, no acute or 
chronic disease, and not taking any medication.
Serum samples were collected and processed at SYSUCC 
Biobank according to standard procedures. In brief, venous 
blood was drawn into serum tubes, clotted at room tem-
perature for 1 h, and subsequently centrifuged at 2,500×g 
for 10 min. Serum was collected, distributed into 100 μL 
aliquots, and immediately stored at −80°C. Repeated 
freeze–thaw cycles were avoided for all serum samples.
Serum proteomic profiling
CRP complex purification from mixed serum
Serum samples from 10 lung cancer patients and from 
10 healthy controls were mixed, respectively. CRP com-
plexes were purified from the mixed cancer serum or 
Table 1 Clinical characteristics of  the recruited patients 
with lung cancer
Patient characteristics were recorded at the time point of blood withdrawal for 
serum analysis.
a Tumor staging was performed according to the seventh edition of the 
International Lung Cancer Staging published by the Union for International 
Cancer Control (UICC) and International Association for the Study of Lung 
Cancer (IASLC).
Characteristic Retrospective cohort Prospective cohort
Total (cases) 222 242
Sex [cases (%)]
 Male 169 (76.1) 176 (72.7)
 Female 53 (23.9) 66 (27.3)
Age (years)
 Median 59 59
 Range 28–91 31–79
Tumor clinical stagea [cases (%)]
 I 37 (16.6) 39 (16.1)
 II 43 (19.4) 40 (32.6)
 III 71 (32.0) 99 (40.9)
 IV 71 (32.0) 64 (26.4)
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mixed control serum using the following method. In 
brief, after centrifugation at 10,000×g for 10  min at 
4°C, 500  μL of serum was diluted in 500  μL of buffer 
(20  mmol/L Tris–HCl, 150  mmol/L NaCl, 5  mmol/L 
CaCl2, 0.1% Nonidet P-40, pH 7.4), and CRP com-
plexes were precipitated by shaking overnight at 4°C 
using 500 μL of anti-CRP carboxyl-coated polyethylene 
beads (Stagnant Water Co., Osaka, Japan). The beads 
were washed 5 times with dilution buffer by centrifuga-
tion at 10,000×g for 10 min at 4°C, and the supernatant 
with unbound proteins was removed. The pellets were 
solubilized in 100 μL of triethyl-ammonium bicarbonate 
(TEAB) lysis buffer (20 mmol/L TEAB, 20 mmol/L DL-
dithiothreitol [DTT], 1% sodium dodecyl sulfate [SDS]) 
at room temperature for 10  min, heated to 95°C for 
10 min, and then allowed to cool for a further 10 min at 
room temperature. Samples containing the affinity-puri-
fied proteins were subjected to an additional centrifuga-
tion step (10,000×g for 30 min at room temperature), and 
the supernatants were collected.
Sodium dodecyl sulfate–polyacrylamide gelelectrophoresis 
(SDS‑PAGE) and liquid chromatograph‑mass spectrometry/
mass spectrometry (LC–MS/MS) analysis
The affinity-purified proteins were applied to 8%–14% 
gradient gels for SDS-PAGE. After staining with 0.5% 
Coomassie brilliant blue G-250, the lane with a molecular 
weight of approximately 12 kDa, which was only present 
in serum from lung cancer patients and not in healthy 
control serum, was excised and subjected to in-gel tryp-
tic digestion. After in-gel digestion with trypsin, the 
extracted peptide mixtures were loaded onto a nanoscale 
LC-ESI-Q-TOF MS instrument (Q-TOF Micromass 
Spectrometer, Waters Co., Milford, MA, USA) for pro-
tein identification. All data generated from the gel section 
were used to search the international protein index (IPI) 
human database (v3.61) using Paragon Algorithm 21, 
which is integrated into the Protein Pilot search engine 
(v.3; AB SCIEX, Foster, CA, USA).
Two‑dimensional electrophoresis (2‑DE) and matrix‑assisted 
laser desorption ionization time of flight/time of flight mass 
spectrometry (MALDI TOF/TOF MS) analysis
Affinity-purified CRP complexes were subjected to two-
dimensional separation, and 2-DE runs were repeated 
three times. After electrophoresis, the gels were stained 
with blue silver, scanned in a densitometer (Molecu-
lar Imager FX, BioRad company, Hercules, CA, USA) 
at a resolution of 600 dpi, and analyzed using PDQuest 
software (version 7.1.0, BioRad). Protein spots exhibit-
ing twofold or higher change in density (Student’s t test, 
P < 0.05) in a consistent direction were considered to be 
different and selected for further identification.
Peptide extraction
Protein spots of interest were in-gel digested by trypsin. 
Gel pieces were first discolored in 50% acrylonitrile 
(ACN) and 25  mmol/L ammonium bicarbonate and 
subsequently subjected to reduction in 10 mmol/L DTT 
and alkylation in 55  mmol/L iodoacetic acid. Follow-
ing vacuum drying, the gel pieces were incubated with 
sequencing grade modified trypsin (Promega Co., Madi-
son, WI, USA) at a final concentration of 0.01  mg/mL 
in 25 mmol/L ammonium bicarbonate for 16 h at 37°C. 
Supernatants were collected, vacuum-dried, and re-dis-
solved in 50% ACN and 0.1% trifluoroacetic acid (TFA) 
for MS analysis.
MALDI TOF/TOF analysis
Tryptic peptides were finally dissolved in MALDI matrix 
(7 mg/mL α-cyano-4-hydroxycinnamic acid in 0.1% TFA 
and 50% ACN), spotted onto 192-well stainless steel 
MALDI target plates, and analyzed using an ABI 4800 
Proteomics Analyzer MALDI TOF/TOF mass spectrom-
eter (Applied Biosystems, Carlsbad, CA, USA). The MS 
together with the MS/MS spectra were searched against 
the IPI Human database version 3.24 using GPS Explor-
erTM Version 3.0 software and MASCOT database 
search algorithms (version 2.0). The following search 
criteria were used: trypsin specificity, cysteine carba-
midomethylation (C), and methionine oxidation (M) as 
variable modifications, 1 trypsin miscleavage allowed, 
100  ppm MS tolerance, and 0.25  Da MS/MS tolerance. 
All identified proteins had protein scores greater than 59 
(P < 0.05) and individual ion scores greater than 21 with 
expected values (P < 0.05). All MS/MS spectra were fur-
ther validated manually.
Co‑immunoprecipitation (IP) of CRP‑bound serum amyloid 
A (SAA) complexes from serum samples and cell culture 
media
CRP‑SAA complex expression in cell culture media
293FT cells were maintained in our lab and cultured in 
dulbecco’s modified eagle medium (DMEM) (Gibco, 
Grand Island, NY, USA) supplemented with 10% fetal 
bovine serum (Gibco) and 1% penicillin/streptomycin 
(Gibco). For transfections, we used the pSPHis plasmid 
vector, pSPHis-CRP, and pSPHis-SAA recombinant plas-
mid which were all constructed and preserved by our 
laboratory, and these plasmids can effectively express 
secreted proteins from inserted gene fragments. A CRP-
secreting 293FT stable cell line (293FT-CRP) was estab-
lished through transfection of the pSPHis-CRP plasmid, 
and a SAA-secreting 293FT stable cell line (293FT-SAA) 
was established by transfection with the pSPHis-SAA 
plasmid. The 293FT-CRP and 293FT-SAA cell lines 
were mixed in equivalent numbers for culture. After 
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incubation for 24 h, cells were washed twice with serum-
free DMEM, then further incubated for 48  h in serum-
free DMEM. The cell culture media were collected and 
centrifuged at 2,000×g for 20 min, and the supernatants, 
which contained CRP-SAA complexes, were collected.
Co‑IP of CRP‑SAA complexes
Similar to the method for purification of CRP complexes, 
the CRP-SAA complexes from the serum samples or the 
cell supernatants were evaluated by IP using anti-CRP 
carboxyl-coated polyethylene beads (Stagnant Water 
Co.), followed by immunoblotting with anti-SAA poly-
clonal antibody (sc-20651, Santa Cruz, Dallas, TX, USA). 
The CRP-SAA complexes were also evaluated by IP with 
anti-SAA polyclonal antibody and protein A/G beads 
(20423, Pierce, Rockford, IL, USA), and immunoblot-
ting with an anti-CRP antibody (ab13426, Abcam, Cam-
bridge, UK).
Western blotting
Purified CRP complexes were resolved using 12% SDS-
PAGE. The proteins were then transferred to polyvi-
nylidene difluoride (PVDF) membranes and incubated 
with anti-SAA or anti-CRP antibodies after blocking. The 
membrane was washed with phosphate-buffered saline 
with tween (PBST) and then incubated with horserad-
ish peroxidase-conjugated secondary antibodies (Pierce) 
prior to visualization of the bands using enhanced chemi-
luminescence western blotting substrate (32106, Pierce).
Immunohistochemical assay
Anti-SAA polyclonal rabbit antibody was used as the pri-
mary antibody. The immunohistochemical kit (SP-9001 
rabbit SP kit, 50581654) was obtained from Zhongshan 
Golden Bridge Co. Ltd. (Beijing, China). The anti-SAA 
polyclonal antibody was incubated overnight at 4°C. 
After washing with phosphate-buffered saline (PBS), the 
biotinylated secondary antibody of the kit was applied 
for 15  min at 37°C. Then, the sections were incubated 
with streptavidin–horseradish peroxidase complex and 
developed with 3′-diaminobenzidine tetrahydrochloride 
(DAB). Light Mayer’s hematoxylin (Zhongshan Golden 
Bridge) was applied as a counterstain.
Enzyme‑linked immunosorbent assay (ELISA)
To detect CRP-bound SAA (CRP-SAA) or total SAA, 
96-well ELISA plates (Corning, Corning, NY, USA) were 
coated with 0.5  μg/mL anti-CRP monoclonal antibody 
(DY1707, R&D, Minneapolis, MN, USA) or 100  ng/well 
anti-SAA polyclonal antibody in 0.05  mol/L NaHCO3, 
pH 9.0, overnight at 4°C, followed by blocking with 3% 
bovine serum albumin in PBS for 3  h at 37°C. Serum 
samples were tested in duplicate; they were diluted at 
1:100 with Signal Boost Solution 1 (407207, Merck Cal-
biochem, Darmstadt, Hesse, Germany) and incubated 
for 2 h at 37°C. After four washes with PBST, the plates 
were incubated with 1:6,000 diluted biotin-labeled anti-
SAA monoclonal antibody (LS-C20534, LifeSpan Bio-
Sciences, Seattle, WA, USA) in Signal Boost Solution 2 
(407207, Merck Calbiochem) for another 2 h at 37°C. The 
plates were then incubated with 1:5,000 HRP-labeled avi-
din (43-4323, Invitrogen, Carlsbad, CA, USA). After four 
washes with PBST, color was developed using tetrame-
thyl benzidine substrate, and the optical density (OD) at 
450  nm was measured. Every serum sample was tested 
three times, and the average OD value was recorded.
For the detection of serum CRP, we chose the classic 
quantitative method. Serum CRP was measured by parti-
cle-enhanced immunoturbidimetry (Wako, Osaka, Japan) 
using a Hitachi 2008 system (Hitachi, Tokyo, Japan).
Statistical analysis
Statistical analyses were mainly conducted using the 
SPSS 16.0 statistical software package (SPSS Inc., Chi-
cago, IL, USA). Receiver operating characteristic (ROC) 
curve analyses were used to compare the sensitivity and 
specificity for the detection of CRP-SAA and total SAA. 
The Mann–Whitney U test was used to analyze associa-
tions between the levels of CRP-SAA, total SAA and clin-
ical characteristics. Survival curves were plotted using 
the Kaplan–Meier method and compared using the log-
rank test. The significance of various variables in survival 
outcomes was assessed by applying the Cox proportional 
hazards model to the univariate and multivariate analy-
ses. P < 0.05 was considered significant in all cases.
Results
Identification of CRP‑SAA complexes in the serum of lung 
cancer patients
CRP-bound components in serum samples obtained 
from healthy controls or lung cancer patients were puri-
fied using anti-CRP carboxyl-coated polyethylene beads 
and subjected to SDS-PAGE. Gel bands show a mass of 
12–14 kDa, indicating CRP complexes, in the serum sam-
ples from lung cancer patients but not in healthy control 
samples (Fig. 1a). These bands were selected for protein 
identification. The SAA peptide fragments (SAA1/SAA2) 
were frequently identified in subsequent LS-MS/MS 
analysis and covered 69.7% of the amino acid sequences 
of SAA (IPI00552578). These data suggested that CRP 
formed a complex with SAA in the serum samples from 
lung cancer patients.
For further confirmation, serum CRP-bound compo-
nents from healthy controls or lung cancer patients were 
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evaluated using 2-DE. The protein spots with discrepan-
cies between healthy controls and lung cancer patients 
were analyzed using MALDI TOF/TOF MS (Fig.  1b). 
CRP-bound components with significant differential 
expression (twofold or more change, P < 0.05, Student’s 
t-test) in the serum samples from lung cancer patients are 
shown in Table 2. SAA1/SAA2 (IPI00552578) and SAA2 
isoform A (IPI00006146) exhibited 79.5% amino acid 
sequence coverage in the MS analysis (Fig. 1b). Because 
the protein homology between SAA1 and SAA2 is 95.9%, 
we hereafter used SAA to indicate both SAA1 and SAA2.
Confirmation of CRP‑SAA complexes in serum samples or 
cell culture media and expression of SAA in lung cancer 
tissues
SAA is known as an acute-phase protein and has been 
reported to be elevated in the serum of lung cancer 
patients [17]. We detected the existence of CRP-SAA in 
the mixed serum sample from 10 lung cancer patients on 
which we previously performed the proteomics analysis 
(Fig.  2a) and some serum samples from individual lung 
cancer patients (Fig.  2b) by co-IP. The property of CRP 
binding to SAA was also confirmed in the media from 
Fig. 1 Identification of serum C‑reactive protein‑bound serum amyloid A (CRP‑SAA) complexes in serum samples from lung cancer patients. a 
Sodium dodecyl sulfate–polyacrylamide gelelectrophoresis (SDS‑PAGE) and mass spectrometry (MS) of serum samples from healthy controls and 
lung cancer patients. The red frame indicates the discrepant bands. b Analysis of discriminative masses between normal and cancer serum samples 
through two‑dimensional electrophoresis (2‑DE) and MS. The red arrows indicate the discrepant masses corresponding to SAA1/SAA2 proteins.
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Fig. 2 Confirmation of CRP‑SAA complexes in the serum samples or cell culture media and expression of SAA in lung cancer tissues. a Identifica‑
tion of CRP‑SAA complexes in mixed serum from ten healthy controls and from ten lung cancer patients through co‑immunoprecipitation (co‑IP). 
b Identification of CRP‑SAA complexes in serum samples from individual healthy controls and lung cancer patients through co‑IP. c Identification 
of CRP‑SAA complexes in culture media from mixed 293FT‑CRP and 293FT‑SAA cells through co‑IP. d Immunohistochemical assay shows high 
expression of SAA in both lung adenocarcinoma and squamous cell carcinoma tissues and low expression in normal lung tissues. e Enzyme‑linked 
immunosorbent assay (ELISA) for the detection of CRP‑SAA and total SAA. f The standard curve of the ELISA system for CRP‑SAA using serially 
diluted culture media from mixed 293FT‑CRP and 293FT‑SAA cells.
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mixed cultivation of the 293FT-CRP and 293FT-SAA cell 
lines (Fig. 2c).
Recently, it was reported that melanoma cells can pro-
duce SAA, although SAA is typically known as a primary 
product of hepatocytes [18]. We found that SAA was 
highly expressed in lung cancer tissue but expressed at 
low levels in normal lung tissues (Fig. 2d).
Next, we investigated whether CRP-SAA or total SAA 
in serum could be used as a lung cancer marker. We 
established two ELISA systems: one to detect total SAA, 
in which two different SAA antibodies were used in 
coating and detection, and another to detect CRP-SAA, 
in which anti-CRP antibodies were used to capture CRP 
complexes and biotin-labeled anti-SAA antibodies were 
used to detect CRP-SAA (Fig. 2e).
To evaluate the efficacy of the ELISA for CRP-SAA 
detection, mixed culture media of 293FT-CRP and 293FT-
SAA cells were diluted serially to prepare a standard curve 
for ELISA of CRP-SAA. The R value of the standard curve 
was 0.998,5, indicating that this ELISA system can effec-
tively determine the levels of CRP-SAA (Fig. 2f).
Association of elevated serum CRP‑SAA level with clinical 
features of lung cancer
The serum levels of CRP-SAA and total SAA were 
evaluated in samples from two independent cohorts 
of lung cancer patients and healthy control samples 
using the two ELISA systems. Similar to total SAA, the 
serum levels of CRP-SAA in patients with lung can-
cer were elevated significantly compared with those 
in healthy controls (P < 0.001) (Fig. 3a). ROC analysis 
showed that the area under the ROC curve (AUC) for 
CRP-SAA in the diagnosis of lung cancer was 0.903, 
which was higher than the AUC of 0.845 obtained 
for total SAA (Fig.  3b). In addition, patients with 
advanced-stage cancers had higher levels of CRP-SAA 
and total SAA compared with those with early-stage 
cancers (Fig. 3c).
ROC analysis showed that ODs of 0.10 for CRP-SAA 
and 0.17 for total SAA were the optimal cutoff values 
to divide patients into low-level and high-level groups, 
respectively. Statistical analysis of clinical data between 
the low- and high-level groups of lung cancer patients 
revealed that the serum levels of CRP-SAA were closely 
associated with sex, smoking status, tumor size, lymph 
node involvement, distant metastasis, and clinical stage 
(Table 3). Similar to total SAA, high levels of CRP-SAA 
indicated severe clinical features.
Prognostic value of CRP‑SAA in the retrospective cohort 
of lung cancer patients
We evaluated whether CRP-SAA could be a prognos-
tic marker for lung cancer. In the retrospective cohort, 
patients with high levels of CRP-SAA showed a shorter 
median survival than those with low levels of CRP-SAA 
(Fig. 4a). The 5-year overall survival (OS) rate was lower 
in the high-level group than in the low-level group (9.5% 
vs. 29.9%). When patients were stratified by cancer 
stages, a high level of CRP-SAA was also associated with 
a shorter median survival in the stages I–II (Fig. 4b) and 
stages III–IV subgroups (Fig. 4c; Table 4).
Furthermore, the prognostic value of CRP-SAA was com-
pared with those of total SAA and CRP. The cutoff value of 
CRP used for grouping was 8 mg/L, as determined by ROC 
analysis. High levels of both total SAA and CRP were asso-
ciated with shorter survival in the whole cohort and the 
stages III-IV subgroup, but not in the stages I-II subgroup; 
the 5-year OS rate was lower in the high-level group than 
in the low-level group for both total SAA (14.3% vs. 27.6%) 
and CRP (9.6% vs. 29.7%) (Fig. 4d–i; Table 4).
Prognostic value of CRP‑SAA in an independent 
prospective cohort of lung cancer patients
To confirm the prognostic value of CRP-SAA, we 
recruited an independent prospective cohort of patients 
and followed their survival for 4  years. Consistent with 
the results obtained from the retrospective cohort, high 
levels of CRP-SAA were associated with shorter survival 
in the whole prospective cohort, the stages I–II sub-
group, and the stages III–IV subgroup; high levels of total 
SAA and CRP were associated with shorter survival in 
the whole prospective cohort and the stages III–IV sub-
group, but not in the stages I-II subgroup (Fig. 5; Table 4).
Potential prognostic value of CRP‑SAA for lung cancer
The results of univariate and multivariate Cox regres-
sion analyses of the prognostic values of various factors 
in the 464 lung cancer patients are presented in Tables 5 
and 6. Multivariable analysis, adjusted for age, sex, smok-
ing status, clinical stage, and treatment regimen, showed 
that CRP-SAA was an independent prognostic factor 
for OS in the whole cohort, the stages I–II subgroup, 
and the stages III-IV subgroup (all P < 0.005); total SAA 
and CRP were also independent prognostic factors for 
OS in the whole cohort and the stages III–IV subgroup 
(all P  <  0.005), but not in the stages I–II subgroup (all 
P > 0.05; Table 6).
Discussion
Through a differential proteomic analysis, we found that 
several proteins were significantly up-regulated in the 
form of CRP-bound complexes in the serum of lung can-
cer patients. SAA was exclusively presented in the form 
of CRP-bound complexes in the serum of lung cancer 
patients. Further in  vitro studies confirmed that CRP 
could bind to SAA. SAA is known to be an acute-phase 
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Fig. 3 CRP‑SAA is a potential diagnostic marker for lung cancer. a The serum levels of both CRP‑SAA and total SAA in lung cancer patients (n = 464) 
are elevated significantly compared with those in healthy controls (n = 159). b Receiver operating characteristic (ROC) curve analysis shows that the 
area under the ROC curve (AUC) is 0.903 for CRP‑SAA and 0.845 for total SAA in the diagnosis of lung cancer. c Patients with advanced‑stage cancers 
had higher levels of both CRP‑SAA and total SAA compared with those with early‑stage cancers.
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Table 3 Association between serum levels of CRP-bound SAA (CRP-SAA), total SAA and clinical characteristics of the 464 
lung cancer patients
The Mann-Whitney U test was used to analyze the associations. Tumor size, lymph node involvement, distant metastasis, and clinical stage were classified according to 
the seventh edition of the Union for International Cancer Control (UICC) Staging system for Lung Cancer.
P < 0.05 is considered significant and the P-value is in italics.
OD optical density.
Characteristic CRP‑SAA [cases (%)] P value Total SAA [cases (%)] P value
Low level (OD ≤ 0.10) High level (OD > 0.10) Low level (OD ≤ 0.17) High level (OD > 0.17)
Total 212 252 271 193
Age 0.725 0.741
 <60 years 112 (24.1) 129 (27.8) 139 (30.0) 102 (22.0)
 ≥60 years 100 (21.6) 123 (26.5) 132 (28.4) 91 (19.6)
Sex 0.001 0.106
 Male 142 (30.6) 203 (43.8) 194 (41.8) 151 (32.5)
 Female 70 (15.1) 49 (10.6) 77 (16.6) 42 (9.1)
Smoking status <0.001 <0.001
 No 113 (24.4) 85 (18.3) 139 (30.0) 59 (12.7)
 Yes 99 (21.3) 167 (36.0) 132 (28.4) 134 (28.9)
Treatment <0.001 <0.001
 Multimodality therapy  
without operation
86 (18.5) 54 (11.6) 112 (24.1) 28 (6.0)
 Operation alone 62 (13.4) 76 (16.4) 82 (17.7) 56 (12.1)
 Operation and  
multimodality therapy
64 (13.8) 122 (26.3) 77 (16.6) 109 (23.5)
T stage <0.001 <0.001
 T1 41 (8.8) 29 (6.3) 54 (11.6) 16 (3.4)
 T2 109 (23.5) 100 (21.6) 130 (28.0) 79 (17.0)
 T3 32 (6.9) 82 (17.7) 51 (11.0) 63 (13.6)
 T4 30 (6.5) 41 (8.8) 36 (7.8) 35 (7.5)
N stage <0.001 <0.001
 N0 93 (20.0) 72 (15.5) 113 (24.4) 52 (11.2)
 N1 33 (7.1) 41 (8.8) 47 (10.1) 27 (5.8)
 N2 68 (14.7) 90 (19.4) 84 (18.1) 74 (15.9)
 N3 18 (3.9) 49 (10.6) 27 (5.8) 40 (8.6)
M stage <0.001 <0.001
 M0 174 (37.5) 155 (33.4) 213 (45.9) 116 (25.0)
 M1 38 (8.2) 97 (20.9) 58 (12.5) 77 (16.6)
Clinical stage <0.001 <0.001
 I 57 (12.3) 19 (4.1) 61 (13.1) 15 (3.2)
 II 41 (8.8) 42 (9.1) 60 (12.9) 23 (5.0)
 III 76 (16.4) 94 (20.3) 92 (19.8) 78 (16.8)
 IV 38 (8.2) 97 (20.9) 58 (12.5) 77 (16.6)
Pathologic type 0.192 0.784
 Adenocarcinoma 112 (24.1) 131 (28.2) 147(31.7) 96(20.7)
 Squamous cell carcinoma 65 (14.0) 65 (14.0) 72 (15.5) 58 (12.5)
 Small cell carcinoma 15 (3.2) 33 (7.1) 26 (5.6) 22 (4.7)
 Others 20 (4.3) 23 (5.0) 26 (5.6) 17 (3.7)
Primary tumor site 0.821 0.301
 Left lung 86 (18.5) 107 (23.1) 105 (22.6) 88 (19.0)
 Right lung 126 (27.2) 145 (31.3) 166 (35.8) 105 (22.6)
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high levels of CRP-SAA were associated with shorter 
survival in both retrospective and prospective cohorts of 
lung cancer patients. Our data agree with the results of 
previous studies in which increased SAA and CRP levels 
were found to be useful biomarkers for the prediction of 
lung cancer prognosis [17, 24]. Remarkably, in stages I–II 
patients, only CRP-SAA and not total SAA or CRP sig-
nificantly predicted OS. Moreover, univariate and mul-
tivariate Cox analyses also showed that only CRP-SAA 
could be used as an independent prognostic marker for 
early-stage patients.
The performance of CRP-SAA in lung cancer progno-
sis may be related to its biological functions. The roles 
Fig. 4 Prognostic values of serum CRP‑SAA, total SAA, and CRP in the retrospective cohort of lung cancer patients. a Kaplan–Meier survival curves 
of the 242 patients divided by the cutoff optical density (OD) value for CRP‑SAA into low‑level (OD ≤ 0.10) and high‑level (OD > 0.10) groups. b Sur‑
vival curves of 79 patients at stages I–II divided by the cutoff value for CRP‑SAA into low‑ and high‑level groups. c Survival curves of 163 patients at 
stages III‑IV divided by the cutoff value for CRP‑SAA into low‑ and high‑level groups. d Survival curves of the 242 patients divided by the cutoff OD 
value for total SAA into low‑level (OD ≤ 0.17) and high‑level (OD > 0.17) groups. e Survival curves of 79 patients at stages I–II divided by the cutoff 
value for total SAA into low‑ and high‑level groups. f Survival curves of 163 patients at stages III–IV divided by the cutoff value for total SAA into 
low‑ and high‑level groups. g Survival curves of the 242 patients divided by the cutoff value for CRP into low‑level (CRP ≤ 8 mg/L) and high‑level 
(CRP > 8 mg/L) groups. h Survival curves of 79 patients at stages I–II divided by the cutoff value for CRP into low‑ and high‑level groups. i Survival 
curves of 163 patients at stages III–IV divided by the cutoff value for CRP into low‑ and high‑level groups. Significant differences were calculated 
using a log‑rank test. The numbers of patients at risk at each specific time point are indicated. The number of events indicates the cumulative num‑
ber of all events during the entire follow‑up period. HR hazard ratio calculated by univariate Cox regression analysis, not adjusted by other factors. CI 
confidence interval.
protein and is more sensitive than CRP for predicting the 
prognosis of cancer. Recently, many reports have identi-
fied close relationships between elevated SAA in serum 
and worse prognoses of several types of cancers [19–22]. 
SAA was reported to be a potential diagnostic and prog-
nostic biomarker for lung cancer [23, 24]. In our study, 
we first found that CRP bound to SAA and formed com-
plexes in the serum of lung cancer patients. A sandwich 
ELISA was developed to detect serum CRP-SAA levels 
and evaluate their prognostic value.
Similar to total SAA, high levels of CRP-SAA were 
closely associated with the clinical features of lung can-
cer patients. Moreover, similar to total SAA and CRP, 
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Table 4 Associations of  CRP-SAA, total SAA, and  CRP with  survival of  lung cancer patients in  both the retrospective 
cohort and the prospective cohort
Abbreviations as in previous Tables. “–” indicates that the cumulative survival rate is below 50%. For grouping, the cutoff OD value for CRP-SAA is 0.10; the cutoff OD 
value for total SAA is 0.17; and the cutoff value of CRP is 8 mg/L.
Variate The retrospective cohort The prospective cohort
Stages I–IV Stages I–II Stages III–IV Stages I–IV Stages I–II Stages III–IV
CRP‑SAA
 High level 33.1 – 21.48 – – –
 Low level 14.9 – 14.15 – – –
 HR 2.181 1.999 1.808 2.744 2.613 2.209
 95% CI 1.641–2.897 1.070–3.737 1.307–2.500 1.810–4.161 1.211–5.635 1.336–3.652
 P value <0.001 0.026 <0.001 <0.001 0.01 0.001
Total SAA
 High level 30.25 – 21.04 – – –
 Low level 16.46 – 14.6 – – –
 HR 1.697 1.27 1.631 1.775 0.44 1.602
 95% CI 1.281–2.248 0.692–2.331 1.180–2.255 1.243–2.533 0.105–1.851 1.079–2.378
 P value <0.001 0.436 0.002 0.001 0.246 0.016
CRP
 High level 30.59 – 21.35 – – –
 Low level 15.68 – 14.15 – – –
 HR 2.03 1.565 1.794 2.185 1.64 1.874
 95% CI 1.529–2.696 0.828–2.959 1.299–2.477 1.534–3.112 0.774–3.474 1.238–2.836
 P value <0.001 0.162 <0.001 0.001 0.189 0.002
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Fig. 5 Prognostic values of serum CRP‑SAA, total SAA, and CRP in the prospective cohort of lung cancer patients. a Kaplan–Meier survival curves of 
the 222 patients divided by the cutoff OD value for CRP‑SAA into low‑ and high‑level groups. b Survival curves of 80 patients at stages I–II divided 
by the cutoff value for CRP‑SAA into low‑ and high‑level groups. c Survival curves of 142 patients at stages III–IV divided by the cutoff value for 
CRP‑SAA into low‑ and high‑level groups. d Survival curves of the 222 patients divided by the cutoff OD value for total SAA into low‑ and high‑level 
groups. e Survival curves of 80 patients at stages I–II divided by the cutoff value for total SAA into low‑ and high‑level groups. f Survival curves of 
142 patients at stages III–IV divided by the cutoff value for total SAA into low‑ and high‑level groups. g Survival curves of the 222 patients divided by 
the cutoff value for CRP into low‑ and high‑level groups. h Survival curves of 80 patients at stages I–II divided by the cutoff value for CRP into low‑ 
and high‑level groups. i Survival curves of 142 patients at stages III–IV divided by the cutoff value for CRP into low‑ and high‑level groups.
Table 5 Univariate and Multivariate Cox regression analysis of potential prognostic factors for 464 lung cancer patients
“−”, age and sex are not included in the Multivariate Cox regression analysis. Other footnotes as in Table 4.
Variable Univariate model Multivariate model
HR 95% CI P HR 95% CI P
Age – – –
 <60 years 1.000
 ≥60 years 1.151 0.926–1.432 0.206
Sex – – –
 Female 1.000
 Male 1.285 0.997–1.657 0.053
Smoking status
 No 1.000 1.000
 Yes 1.533 1.224–1.919 <0.001 1.462 1.080–1.980 0.014
Treatment
 Multimodality therapy without operation 1.000 1.000
 Operation alone 0.231 0.173–0.309 <0.001 0.568 0.367–0.880 0.011
 Operation and multimodality therapy 0.326 0.250–0.425 <0.001 0.492 0.362–0.669 <0.001
T stage
 T1 1.000 1.000
 T2 1.176 0.820–1.686 0.378 1.081 0.753–1.552 0.671
 T3 2.019 1.382–2.951 <0.001 1.352 0.920–1.987 0.124
 T4 2.162 1.436–3.253 <0.001 1.013 0.668–1.536 0.951
N stage
 N0 1.000 1.000
 N1 1.043 0.730–1.489 0.817 0.789 0.549–1.133 0.199
 N2 1.756 1.346–2.293 <0.001 0.797 0.599–1.058 0.117
 N3 2.725 1.958–3.793 <0.001 1.155 0.816–1.636 0.416
M stage
 M0 1.000 1.000
 M1 3.091 2.448–3.902 <0.001 0.985 0.681–1.424 0.936
Clinical stage
 I 1.000 1.000
 II 3.742 2.213–6.325 <0.001 3.254 1.909–5.546 <0.001
 III 5.267 3.239–8.563 <0.001 3.435 2.013–5.864 <0.001
 IV 11.25 6.855–18.461 <0.001 5.685 3.063–10.549 <0.001
CRP‑SAA
 Low level 1.000 1.000
 High level 2.097 1.673–2.628 <0.001 1.545 1.223–1.951 <0.001
Total SAA
 Low level 1.000 1.000
 High level 1.778 1.429–2.212 <0.001 1.329 1.061–1.663 0.013
CRP
 Low level 1.000 1.000
 High level 2.045 1.641–2.549 <0.001 1.454 1.156–1.829 0.001
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of SAA in the context of tumorigenesis include binding 
to extracellular matrix (ECM) components [25], enhanc-
ing plasminogen activation [26], and stimulating matrix 
metalloproteinase (MMP) production [27]. A recent 
study reported that the overexpression of SAA could 
promote Lewis lung carcinoma cell metastasis and lung 
colonization in animal models and that the expression 
of SAA was induced when lung cancer cells were co-
cultured with macrophages or cytokines [28]. De Santo 
et  al. [18] reported that melanoma cells produce SAA, 
which facilitates tumor growth by inducing neutrophils 
to secrete interleukin-10 (IL-10), resulting in a suppres-
sive immune response. Because CRP can recognize both 
Fc α receptor I (FcαRI) and Fc γ receptor (FcγR) on mac-
rophages, we presume that the CRP-SAA complex could 
help SAA to bind to macrophages and induce suppres-
sive immune responses or promote MMP production. 
These properties may increase the importance of SAA 
or CRP-SAA in tumor pathogenesis and metastasis. In 
our study, we also found that SAA was highly expressed 
in lung cancer tissues; therefore, we presume that cir-
culating CRP may easily contact SAA produced by lung 
cancer cells to form the CRP-SAA complex, and the 
appearance of CRP-SAA in the serum could be a predic-
tive biomarker for lung cancer progression. Moreover, 
high serum levels of CRP-SAA but not total SAA or CRP 
in the present study were significantly associated with a 
worse prognosis in patients with early-stage lung cancer, 
suggesting that the elevation of serum CRP-SAA levels 
may result from both the increased production of SAA 
in the tumor microenvironment and the elevated pro-
duction of CRP by the liver in response to the chronic 
inflammation of the tumor site in early stages. Therefore, 
CRP-SAA levels could be considered a more sensitive 
and relevant indicator of early lung cancer progression 
than CRP or SAA alone.
In addition to lung cancer, elevated levels of CRP 
and SAA have been observed in other types of cancer, 
including gastric cancer [29], esophageal squamous cell 
carcinoma [18], and breast cancer [30]. It would thus 
be interesting to determine whether CRP-SAA could 
serve as a potential prognostic marker in these cancers. 
Moreover, for potential clinical application, it is impor-
tant to determine whether the elevated CRP-SAA level 
is restricted to cancer patients or whether it is associated 
with other chronic inflammatory diseases.
In conclusion, the present study reveals that serum 
CRP-SAA isolated from serum CRP-bound complexes 
is a potential marker for poor prognosis in lung cancer 
patients. The prognostic value of CRP-SAA is higher than 
Table 6 Stratified Cox regression analysis of CRP-SAA, Total SAA, and CRP for 464 lung cancer patients
a Each serum marker was analyzed separately in the model, adjusting for age, sex, smoking status, clinical stage, and treatment. Abbreviations as in previous tables.
Variable Univariate model Multivariate modela
HR 95% CI P HR 95% CI P
Stages I–II
 CRP‑SAA
  Low level 1.000 1.000
  High level 2.583 1.873–3.560 <0.001 1.677 1.188–2.368 0.003
 Total SAA
  Low level 1.000 1.000
  High level 1.581 1.164–2.150 0.003 1.180 0.859–1.620 0.307
 CRP
  Low level 1.000 1.000
  High level 2.113 1.563–2.857 <0.001 1.429 1.036–1.971 0.063
Stages III–IV
 CRP‑SAA
  Low level 1.000 1.000
  High level 1.899 1.483–2.431 <0.001 1.594 1.237–2.052 <0.001
 Total SAA
  Low level 1.000 1.000
  High level 1.879 1.485–2.377 <0.001 1.359 1.065–1.735 0.014
 CRP
  Low level 1.000 1.000
  High level 1.970 1.554–2.499 <0.001 1.507 1.178–1.929 0.001
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that of CRP and SAA individually, especially for early-
stage lung cancer patients.
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